Latest Us Market News

HeraMED reports a surge in its HeraCARE platform users and secures $4.1 million in new funding, underpinning its expansion in the US maternity care market and integration with major health systems.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

NoviqTech's December quarter report reveals a strategic $1.05 million capital raise, a significant HBAR token purchase, and expanding partnerships that position the company at the forefront of blockchain-powered sustainability solutions.

Connexion Mobility Limited reported a robust 15% revenue increase and a 43% jump in profit after tax for the half-year ended December 2024, underscoring its growing foothold in automotive SaaS solutions while continuing to invest in future growth.

Pure Hydrogen advances its zero-emission vehicle strategy with key deliveries, US partnerships, and a planned demerger of its natural gas assets into Eastern Gas Limited.

Lumos Diagnostics reported a robust Q2 FY25 with a 71% revenue increase to US$2.9 million, driven by strong product and service sales, alongside a strategic US$3 million BARDA partnership to advance its FebriDx test.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

xReality Group Limited has reported its strongest quarter yet, with cash receipts soaring 87% year-on-year to $5.2 million, driven by robust growth in its Operator XR enterprise software and entertainment divisions.

TZ Limited reported a quarterly revenue shortfall in Q2 FY2025 due to delayed US projects but anticipates a strong rebound post-election and strategic growth through acquisition.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

Adherium reports strong patient adoption and new US partnerships, positioning for significant expansion in 2025 with a target of 9,000 active users and entry into the Pharmacy Benefit Management sector.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.